Jazmati, D.; Hero, B.; Thole.-Kliesch, T.M.; Merta, J.; Deubzer, H.E.; Bäumer, C.; Heinzelmann, F.; Schleithoff, S.S.; Koerber, F.; Eggert, A.;
et al. Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry. Curr. Oncol. 2022, 29, 8222-8234.
https://doi.org/10.3390/curroncol29110649
AMA Style
Jazmati D, Hero B, Thole.-Kliesch TM, Merta J, Deubzer HE, Bäumer C, Heinzelmann F, Schleithoff SS, Koerber F, Eggert A,
et al. Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry. Current Oncology. 2022; 29(11):8222-8234.
https://doi.org/10.3390/curroncol29110649
Chicago/Turabian Style
Jazmati, Danny, Barbara Hero, Theresa M. Thole.-Kliesch, Julien Merta, Hedwig E. Deubzer, Christian Bäumer, Feline Heinzelmann, Stefanie Schulze Schleithoff, Friederike Koerber, Angelika Eggert,
and et al. 2022. "Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry" Current Oncology 29, no. 11: 8222-8234.
https://doi.org/10.3390/curroncol29110649
APA Style
Jazmati, D., Hero, B., Thole.-Kliesch, T. M., Merta, J., Deubzer, H. E., Bäumer, C., Heinzelmann, F., Schleithoff, S. S., Koerber, F., Eggert, A., Schwarz, R., Simon, T., & Timmermann, B.
(2022). Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry. Current Oncology, 29(11), 8222-8234.
https://doi.org/10.3390/curroncol29110649
